0001209191-14-074579.txt : 20141211
0001209191-14-074579.hdr.sgml : 20141211
20141211171000
ACCESSION NUMBER: 0001209191-14-074579
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141209
FILED AS OF DATE: 20141211
DATE AS OF CHANGE: 20141211
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS
CENTRAL INDEX KEY: 0000906709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943134940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 4154825300
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC
DATE OF NAME CHANGE: 19980723
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS
DATE OF NAME CHANGE: 19940303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Doberstein Stephen K
CENTRAL INDEX KEY: 0001480111
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24006
FILM NUMBER: 141281528
MAIL ADDRESS:
STREET 1: 129 ELSIE STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94110
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-12-09
0
0000906709
NEKTAR THERAPEUTICS
NKTR
0001480111
Doberstein Stephen K
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO
CA
94158
0
1
0
0
SVP & Chief Scientific Officer
Stock Option
16.31
2014-12-09
4
A
0
50000
0.00
A
2022-12-08
Common Stock
50000
50000
D
Stock Option
16.31
2014-12-09
5
A
0
E
50000
0.00
A
2022-12-08
Common Stock
50000
50000
D
This option was granted on December 9, 2014 and vests in monthly installments over the four-year period following the grant date.
This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of 4 years from the grant date (December 9, 2014). The performance-based vesting condition will be met only if Nektar (or a licensee) files, within five years following the grant date, a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program (average royalty >7.5%) including, without limitation, the following: (1) etirinotecan pegol; (2) NKTR-061/Amikacin Inhale; (3) Ciprofloxacin Dry Powder for Inhalation; or (4) NKTR-181 (an oral opioid analgesic drug candidate).
Gilbert M. Labrucherie, Jr., Attorney-in-Fact
2014-12-11